AU2002216087A1 - Novel substituted imidazotriazinones as pde ii-inhibitors - Google Patents

Novel substituted imidazotriazinones as pde ii-inhibitors

Info

Publication number
AU2002216087A1
AU2002216087A1 AU2002216087A AU1608702A AU2002216087A1 AU 2002216087 A1 AU2002216087 A1 AU 2002216087A1 AU 2002216087 A AU2002216087 A AU 2002216087A AU 1608702 A AU1608702 A AU 1608702A AU 2002216087 A1 AU2002216087 A1 AU 2002216087A1
Authority
AU
Australia
Prior art keywords
pde
inhibitors
novel substituted
substituted imidazotriazinones
imidazotriazinones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002216087A
Inventor
Frank-Gerhard Boss
Dr. Rolf Grosser
Martin Hendrix
Gerhard Konig
Ulrich Niewohner
Dagmar Schauss
Karl-Heinz Schlemmer
Rudy Schreiber
Franz-Josef Van Der Staay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU2002216087A1 publication Critical patent/AU2002216087A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2002216087A 2000-12-21 2001-12-10 Novel substituted imidazotriazinones as pde ii-inhibitors Abandoned AU2002216087A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10064105A DE10064105A1 (en) 2000-12-21 2000-12-21 New substituted imidazotriazinones
DE10064105 2000-12-21
PCT/EP2001/014450 WO2002050078A1 (en) 2000-12-21 2001-12-10 Novel substituted imidazotriazinones as pde ii-inhibitors

Publications (1)

Publication Number Publication Date
AU2002216087A1 true AU2002216087A1 (en) 2002-07-01

Family

ID=7668333

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002216087A Abandoned AU2002216087A1 (en) 2000-12-21 2001-12-10 Novel substituted imidazotriazinones as pde ii-inhibitors

Country Status (15)

Country Link
US (1) US6573263B2 (en)
EP (1) EP1347978B1 (en)
JP (1) JP2004525098A (en)
AR (1) AR034423A1 (en)
AU (1) AU2002216087A1 (en)
CA (1) CA2431965A1 (en)
DE (2) DE10064105A1 (en)
DO (1) DOP2001000297A (en)
ES (1) ES2248228T3 (en)
GT (1) GT200100254A (en)
HN (1) HN2001000281A (en)
PE (1) PE20020756A1 (en)
SV (1) SV2002000776A (en)
UY (1) UY27080A1 (en)
WO (1) WO2002050078A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0113342D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 1
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
ATE392897T1 (en) * 2002-02-04 2008-05-15 Hoffmann La Roche QUINOLINE DERIVATIVES AS NPY ANTAGONISTS
RU2296757C2 (en) * 2002-07-05 2007-04-10 Ф.Хоффманн-Ля Рош Аг Derivatives of quinazoline
EP1539722A1 (en) * 2002-08-07 2005-06-15 F. Hoffmann-La Roche Ag Thiazole derivatives
JP2006219374A (en) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Imidazotriazinone derivative having pde 7 inhibition
NZ631258A (en) 2012-04-25 2016-11-25 Takeda Pharmaceuticals Co Nitrogenated heterocyclic compound
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
JP6280912B2 (en) 2013-03-14 2018-02-14 武田薬品工業株式会社 Heterocyclic compounds
WO2015002230A1 (en) 2013-07-03 2015-01-08 武田薬品工業株式会社 Amide compound
WO2015002231A1 (en) 2013-07-03 2015-01-08 武田薬品工業株式会社 Heterocyclic compound
EP3087060B1 (en) 2013-12-23 2020-05-13 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
EP3091983B1 (en) * 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
SI3597649T1 (en) 2014-04-23 2022-04-29 Dart Neuroscience Llc Compositions containing substituted (1,2,4)triazolo(1,5-a)pyrimidin-7-yl compounds as pde2 inhibitors
WO2016073424A1 (en) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted 5-methyl-[1, 2, 4] triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
BR112017012007B1 (en) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc PDE2-INHIBITORY ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND USE THEREOF IN THE TREATMENT OF A PDE2-MEDIATED DISORDER
BR112017012005B1 (en) 2014-12-06 2023-04-04 Intra-Cellular Therapies, Inc ORGANIC PDE2-INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND USE THEREOF IN THE TREATMENT OF A PDE2-MEDIATED DISORDER
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
EP3285581B1 (en) 2015-03-26 2021-08-11 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
US10195201B2 (en) 2015-05-05 2019-02-05 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
US10647727B2 (en) 2015-06-25 2020-05-12 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2019101970A1 (en) 2017-11-23 2019-05-31 Oslo University Hospital Hf Treatment of tachycardia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK109578A (en) 1977-03-25 1978-09-26 Allen & Hanburys Ltd PROCEDURE FOR MAKING HETEROCYCLIC COMPOUNDS
DE19541264A1 (en) 1995-11-06 1997-05-07 Bayer Ag Purin-6-one derivatives
DE19709877A1 (en) 1997-03-11 1998-09-17 Bayer Ag 1,5-dihydro-pyrazolo [3,4-d] pyrimidinone derivatives
DE59803108D1 (en) * 1997-11-12 2002-03-21 Bayer Ag 2-PHENYL-SUBSTITUTED IMIDAZOTRIAZINONE AS PHOSPHODIESTERASE INHIBITORS
DE19827640A1 (en) * 1998-06-20 1999-12-23 Bayer Ag New imidazotriazine derivatives useful as smooth muscle relaxants for treating e.g. cardiovascular disorders, cerebrovascular disorders, or erectile dysfunction
DE19838705A1 (en) 1998-08-26 2000-03-02 Bayer Ag New dihydro- (1,2,3) -triazolo- [4,5-d] pyrimidin-7-ones

Also Published As

Publication number Publication date
GT200100254A (en) 2002-08-19
WO2002050078A1 (en) 2002-06-27
AR034423A1 (en) 2004-02-25
DE10064105A1 (en) 2002-06-27
EP1347978A1 (en) 2003-10-01
JP2004525098A (en) 2004-08-19
UY27080A1 (en) 2002-07-31
CA2431965A1 (en) 2002-06-27
US6573263B2 (en) 2003-06-03
DE50107316D1 (en) 2005-10-06
SV2002000776A (en) 2002-12-02
EP1347978B1 (en) 2005-08-31
DOP2001000297A (en) 2003-08-15
US20020198377A1 (en) 2002-12-26
HN2001000281A (en) 2003-02-04
PE20020756A1 (en) 2002-10-02
ES2248228T3 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
AU2002216087A1 (en) Novel substituted imidazotriazinones as pde ii-inhibitors
AU2002218266A1 (en) Novel indanylidene compounds
AU2001252574A1 (en) Novel bicyclic compounds
AU2001292518A1 (en) Novel compounds
AU2001239765A1 (en) Novel compounds
AU2002213978A1 (en) Substituted C-cyclohexylmethylamine derivatives
AU2001280167A1 (en) Novel propenohydroxamic acid derivatives
AU2001246998A1 (en) Novel compounds
AU2001281965A1 (en) Novel 6-phenylphenanthridines
AU2001253362A1 (en) Novel compounds
AU2001265871A1 (en) Substituted sulfonylaminopyrimidines
AU2002231077A1 (en) Novel compounds
AU2001254731A1 (en) Substituted phenyluracils
AU2001288110A1 (en) Spiro compounds
AU2001256964A1 (en) Novel compounds
AU2001258255A1 (en) Substituted benzoylcyclohexenones
AU2001289937A1 (en) Substituted 1-aminobutan-3-ol derivatives
AU2001234313A1 (en) Novel phenylheteroalkylamine derivatives
AU2001252575A1 (en) Novel tricyclic compounds
AU2002363600A1 (en) Novel phenyl-propargylether derivatives
AU2001230689A1 (en) Novel compounds
AU2002221923A1 (en) Novel compounds
AU2002216060A1 (en) Novel compounds
AU2001276890A1 (en) Novel compounds
AU2002212263A1 (en) Substituted 5-amino-1-pentene-3-ol derivatives